Global Sample Preparation in Genomics, Proteomics, and Epigenomics Market Strategic Research Report
By Type: DNA Sample Preparation, RNA Sample Preparation, Protein Sample Preparation, Epigenetic Modification Targeted Preparation, Others
By Application: Academic Institutes, and Government Institutes, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: QIAGEN GmbH, Bio-Rad Laboratories, Inc., Danaher Corporation, Merck KGaA, PerkinElmer, Inc., BGI, Cytiva, Illumina, Roche Sequencing Solutions, New England Biolabs, Thermo Fisher Scientific, Miltenyi Biotec, Twist Bioscience
Visão geral
Scope of the Report
The global Sample Preparation in Genomics, Proteomics, and Epigenomics market size is predicted to grow from US$ 180 million in 2025 to US$ 267 million in 2032; it is expected to grow at a CAGR of 6.1% from 2026 to 2032.
Sample preparation in Genomics, Proteomics, and Epigenomics refers to a series of operations that isolate and transform target molecules from raw samples such as tissues or cells to adapt them for downstream high-throughput detection. In genomics, the core of preparation lies in obtaining high-purity, intact DNA through lysis and purification, and then fragmenting it to construct sequencing libraries. Preparation in proteomics is more complex, requiring quantification and enzymatic digestion of proteins after extraction to break them down into peptides, and often necessitating the removal of high-abundance interfering proteins to ensure the sensitivity of mass spectrometry detection. Epigenomics preparation, in addition to these steps, requires the preservation of epigenetic modification information, such as cross-linking chromatin to study protein-DNA interactions, or using bisulfite treatment to convert unmethylated cytosine, thereby locating methylation sites during sequencing. Furthermore, in epigenetic studies involving RNA, degradation must be strictly prevented. The preparation processes for all three require precise optimization based on the specific molecular targets and analytical platforms.
The global market for Sample Preparation in Genomics, Proteomics, and Epigenomics exhibits a pattern of both technological leadership and regional specialization. North America, leveraging its leading instrument companies and large-scale automated platforms, dominates the development of standardized preparation technologies for high-throughput, low-loss samples, maintaining a leading position, particularly in single-cell and micro-sample preparation. Europe, drawing on its deep foundation in structural biology and proteomics, focuses on handling challenging samples, such as membrane protein extraction and post-translational modification enrichment, emphasizing precision and reproducibility. The Asia-Pacific region, with China at its core, is driven by substantial research demand, rapidly emerging in the manufacturing of magnetic bead purification reagents and automated liquid handling workstations, providing cost-effective solutions and gradually moving from import substitution to technology export.
This report presents a comprehensive overview of the global Sample Preparation in Genomics, Proteomics, and Epigenomics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Type
- DNA Sample Preparation
- RNA Sample Preparation
- Protein Sample Preparation
- Epigenetic Modification Targeted Preparation
- Others
Segment by Technology Platform
- Sequencing Platform Pretreatment
- Mass Spectrometry Platform Pretreatment
- Microarray Hybridization Pretreatment
- PCR Platform Pretreatment
- Others
Segment by Complexity
- All Components Preparation
- Subcellular Components Preparation
- Modified and Enriched Components Preparation
- Others
Segment by Application
- Academic Institutes, and Government Institutes
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Others
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global Sample Preparation in Genomics, Proteomics, and Epigenomics market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Academic Institutes, and Government Institutes, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global Sample Preparation in Genomics, Proteomics, and Epigenomics Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 DNA Sample Preparation
- 3.1.3 RNA Sample Preparation
- 3.1.4 Protein Sample Preparation
- 3.1.5 Epigenetic Modification Targeted Preparation
- 3.1.6 Others
- 3.1.7 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Academic Institutes, and Government Institutes
- 4.1.3 Hospitals and Clinics
- 4.1.4 Pharmaceutical and Biotechnology Companies
- 4.1.5 Others
- 4.1.6 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 QIAGEN GmbH
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 Bio-Rad Laboratories, Inc.
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 Danaher Corporation
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 Merck KGaA
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 PerkinElmer, Inc.
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 BGI
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 Cytiva
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 Illumina
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 Roche Sequencing Solutions
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 New England Biolabs
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
- 8.11 Thermo Fisher Scientific
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2032)
- 8.12 Miltenyi Biotec
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2032)
- 8.13 Twist Bioscience
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
What is the size of the global Sample Preparation in Genomics, Proteomics, and Epigenomics market?
What is the forecast CAGR for the Sample Preparation in Genomics, Proteomics, and Epigenomics market?
What is Sample Preparation in Genomics, Proteomics, and Epigenomics?
What are the main segments of the Sample Preparation in Genomics, Proteomics, and Epigenomics market by type?
Which applications drive demand in the Sample Preparation in Genomics, Proteomics, and Epigenomics market?
Who are the key players in the Sample Preparation in Genomics, Proteomics, and Epigenomics market?
Which regions and countries are covered for Sample Preparation in Genomics, Proteomics, and Epigenomics?
What is driving growth in the Sample Preparation in Genomics, Proteomics, and Epigenomics market?
Who should buy the Sample Preparation in Genomics, Proteomics, and Epigenomics market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global Sample Preparation in Genomics, Proteomics, and Epigenomics Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Navadhi Market Research · Biotechnology & Life Sciences